Methylmalonic Acidemia (MMA) Market Size Projected To Reach $12.5 Billion By 2034 With A Cagr Of 5.8%

The Methylmalonic Acidemia (MMA) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Methylmalonic Acidemia (MMA) Market?
The market for methylmalonic acidemia (MMA) has experienced robust growth in the past few years. The size of the market is forecasted to rise from $9.39 billion in 2024 to $9.97 billion in 2025, with the compound annual growth rate (CAGR) pegged at 6.2%. This significant growth during the prior period can be credited to factors such as the rise in metabolic disorders and vitamin deficiencies, an upswing in healthcare expenses, heightened health awareness, growing incidence of genetic disorders, and an expanded demand stemming from a range of end-user sectors.

It is anticipated that the methylmalonic acidemia (MMA) market will experience notable expansion in the coming years, projected to reach $12.50 billion in 2029, marking a compound annual growth rate (CAGR) of 5.8%. Various factors contributing to this growth in the projected timeframe include expanded newborn screening initiatives, enhanced awareness among medical professionals, advancements in gene therapy, increased funding for research into rare diseases, and improving access to specialized treatments. Key trends forecasted for this period entail progress in gene-editing technology, advanced diagnosis methods for early detection, improvements in enzyme replacement therapies, the implementation of precision medicine strategies, and the embrace of newborn genetic screening programs.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22057

What Are the Different Methylmalonic Acidemia (MMA) Market Segments?
The methylmalonic acidemia (MMA) market covered in this report is segmented -

1) By Indication: Acidosis, ket*osis, Hyperammonemia, Hypoglycaemia, Hyperglycaemia, Neutropenia, Other Indications
2) By Disorder Type: Homocystinuria, Isolated Methylmalonic Acidurias, Combined methylmalonic Aciduria
3) By Distribution Channel: Hospitals, Pharmacies, Clinics, Other Distribution Channels

Subsegments:
1) By Acidosis: Metabolic Acidosis, Lactic Acidosis
2) By ket*osis: Starvation-Induced ket*osis, Diabetic ket*oacidosis
3) By Hyperammonemia: Acute Hyperammonemia, Chronic Hyperammonemia
4) By Hypoglycemia: Fasting Hypoglycemia, Reactive Hypoglycemi
5) By Hyperglycemia: Transient Hyperglycemia, Persistent Hyperglycemia
6) By Neutropenia: Severe Neutropenia, Cyclic Neutropenia
7) By Other Indications: Failure to Thrive, Developmental Delays, Neurological Symptoms, Renal Dysfunction

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp

What Are the Primary Drivers Shaping the Methylmalonic Acidemia (MMA) Market?
The escalating prevalence of metabolic ailments and lack of essential vitamins is predicted to stimulate the expansion of the methylmalonic acidemia (MMA) market in the future. Metabolic ailments encompass a variety of conditions where the organism struggles with nutrient processing, energy production, or stabilizing cellular chemical reactions. A deficiency in certain vitamins occurs when the body doesn't possess adequate amounts to maintain normal operations. The increase in these conditions can be attributed to poor dietary habits, inactive routines, and rising stress levels. Contemporary diets usually contain excessive amounts of processed food, sugars, and harmful fats but lack essential nutrients, resulting in vitamin and mineral deficiencies. Metabolic disorders and insufficient vitamins, specifically a lack in vitamin B12, disrupt methylmalonyl-CoA metabolism, leading to a buildup of methylmalonic acid and worsening the symptoms of methylmalonic acidemia (MMA). As an illustration, in November 2024, the National Institutes of Health, a governmental agency in the US, reported that the occurrence of vitamin B12 deficiency elevated from 4.6% to 5.2%, a surge of 507 cases between the third and fourth quarters of 2023. Thus, the escalating prevalence of metabolic ailments and lack of essential vitamins stimulates the expansion of the methylmalonic acidemia (MMA) market.

Which Companies Are Leading in the Methylmalonic Acidemia (MMA) Market?
Major companies operating in the methylmalonic acidemia (MMA) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.

What Are the Major Trends Shaping the Methylmalonic Acidemia (MMA) Market?
Key players in the methylmalonic acidemia (MMA) market are focusing on creating cutting-edge solutions like mRNA-based treatments, aiming to enhance therapeutic outcomes. These advancements target the genetic root causes of MMA and improve enzyme functioning to decrease the buildup of harmful metabolites in those affected. mRNA-based treatments are a unique approach to treatment that utilizes messenger RNA to guide cells in creating specific proteins. These proteins could then ward off or manage diseases, including genetic disorders or infections. For example, Moderna, Inc., an American pharmaceutical and biotech firm, secured approval from the U.S. Food and Drug Administration (FDA) in June 2024 to include mRNA-3705 in the START pilot scheme. This is a significant milestone in the progression of therapies for rare diseases. mRNA-3705 is a trial therapy for MMA caused by MUT deficiency; it aims to replenish the missing enzyme utilizing mRNA technology. This therapy capitalizes on Moderna's private lipid nanoparticle (LNP) system, also employed in the mRNA-3927 project for propionic acidemia. The FDA has accorded mRNA-3705 with orphan drugs, fast track, and rare pediatric disease statuses, thus expediting its development and clinical progression.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report

What Are the Top Revenue-Generating Geographies in the Methylmalonic Acidemia (MMA) Market?
North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (MMA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Methylmalonic Acidemia (MMA) Market?
2. What is the CAGR expected in the Methylmalonic Acidemia (MMA) Market?
3. What Are the Key Innovations Transforming the Methylmalonic Acidemia (MMA) Industry?
4. Which Region Is Leading the Methylmalonic Acidemia (MMA) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.